NCT06095102 (ICONIC-TOTAL) is a Phase 3 clinical trial of JNJ-77242113 in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT06095102?

NCT06095102 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT06095102?

Interventions in NCT06095102: JNJ-77242113, Placebo.

What condition does NCT06095102 study?

NCT06095102 studies Plaque Psoriasis.

Is NCT06095102 still recruiting?

NCT06095102 is currently active, enrolled. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT06095102: ICONIC-TOTAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Active, enrolled Phase 3 Last updated 13 March 2026

What this trial tests

Phase 3 trial testing JNJ-77242113 in Plaque Psoriasis in 311 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

12 October 2023

Primary endpoint
19 June 2024

17 February 2027

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	311
Start date	12 October 2023
Primary completion	19 June 2024
Estimated completion	17 February 2027
Sites	90 locations across Taiwan, United Kingdom, Germany, Hungary, Poland, South Korea, Argentina, Canada

Drugs / interventions tested

JNJ-77242113 — full drug profile →
Placebo

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

12 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.
Drakos A, Torres T, Vender R. · · 2024 · cited 21× · PMID 38258121 · DOI 10.3390/pharmaceutics16010111
Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.
Knight B, Tammara B, Modi NB, Dallas S, et al · · 2025 · cited 7× · PMID 40629250 · DOI 10.1007/s13555-025-01454-7
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.
Stein Gold L, Eyerich K, Merola JF, Torres J, et al · · 2025 · cited 7× · PMID 40439953 · DOI 10.1007/s12325-025-03213-8
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.
Gooderham M, Lain E, Bissonnette R, Huang YH, et al · · 2025 · cited 4× · PMID 41191932 · DOI 10.1056/evidoa2500155
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
Strawn D, Krueger JG, Bissonnette R, Eyerich K, et al · · 2025 · cited 2× · PMID 41424381 · DOI 10.1172/jci.insight.193563
Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis.
Ferreira C, Torres T. · · 2026 · PMID 41817926 · DOI 10.1007/s40257-026-01019-0
IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?
Megna M, D'Agostino M, Feo F, Ventura V, et al · · 2026 · PMID 41709961 · DOI 10.2147/jir.s540848
Selected Abstracts from Elevate-Derm Summer Conference 2025.
· 2025 · PMID 41502958

Verify or expand the search:

Other trials of JNJ-77242113

Trials testing the same drug.

NCT06934226 — A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate · Phase 3 · active not recruiting
NCT06220604 — A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) · Phase 3 · active not recruiting
NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT06143878 — A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis · Phase 3 · active not recruiting
NCT06095115 — A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis · Phase 3 · active not recruiting

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06095102 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing